CD4 T-helper cells
A long read from the University of Cambridge...
The need for a HIV vaccine is still pressing. Its advantages over anti-retroviral drugs are obvious – prevention could lead to the eradication of HIV.
In 2009, a clinical trial in Thailand found that an experimental vaccine against HIV lowered the rate of human infection by 31 per cent.
While promising, there was a significant problem: the vaccine did not offer long-lasting protection because the immune response it generated was very short-lived.
Now, University of Cambridge scientists have helped to discover why – and unlocked a potential solution that gives renewed hope of a long-lasting, effective vaccine.